American Society of Hirudotherapy

Ménière's Disease (Adjunctive)

Investigational adjunct for Ménière's disease with no clinical study identified; standard management (diet, betahistine, intratympanic therapy) remains primary.

Tier C — InvestigationalInvestigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Last Updated: November 17, 2026 · ASH Editorial · based on the books

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for Ménière's disease. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use for Ménière's is investigational.
What evidence exists?
No published clinical study of leech therapy could be verified for this condition. Tier C (investigational). There are no randomized controlled trials. Standard management of Ménière's includes low-sodium diet, diuretics, betahistine (where available), intratympanic dexamethasone or gentamicin for refractory cases, and surgical options (endolymphatic sac decompression, labyrinthectomy) for severe disease.
Main risks
  • Bleeding from bite sites for 6 to 24 hours after detachment (placement near the ear, mastoid)
  • Bruising and tenderness near the ear and upper neck for 5 to 10 days
  • Itching and irritation at bite sites
  • Local skin infection or, rarely, Aeromonas infection (heightened concern near ear)
  • Allergic reaction to leech saliva (uncommon)
  • Temporary worsening of vertigo, tinnitus, or aural fullness for 1 to 2 days
  • Small bite marks that usually fade over weeks to months (rarely a pale spot stays longer)
  • Iron-deficiency anemia from cumulative blood loss across multiple sessions
Who should not consider this
  • Patients on blood thinners (anticoagulants such as warfarin, DOACs or heparin)
  • Patients with hemophilia or other bleeding disorders
  • Patients with anemia
  • Patients with active otitis externa or media
  • Patients with vestibular schwannoma or other retrocochlear pathology not yet evaluated
  • Patients with severe debilitating vertigo who may benefit from intratympanic or surgical intervention
  • Patients with a weakened immune system
  • Patients with severe sensorineural hearing loss in the only hearing ear (risk-benefit unfavorable)
  • Patients without a confirmed Meniere diagnosis by an otologist (other vestibular disorders need different treatment)
  • People with an active infection at the planned application site
  • Patients who are pregnant (leech therapy is not done during pregnancy) or breastfeeding (discuss it with your doctor)
What to ask your clinician
  • Have I had a full ENT and audiometric evaluation, and ruled out other vestibular conditions?
  • Have I tried low-sodium diet, diuretics, and betahistine?
  • Have I been offered intratympanic dexamethasone or gentamicin for refractory disease?
  • What evidence supports leech therapy for Ménière's disease specifically?
  • What is the practitioner's experience and Aeromonas-prevention plan?
  • What is the realistic chance of benefit, and for how long?
  • What is the cost?
  • What hearing tests will be done before and after the course to track changes?
When to seek urgent care
  • Sudden hearing loss in one or both ears (sudden sensorineural hearing loss is an emergency)
  • Sudden severe vertigo with neurologic symptoms — weakness, numbness, double vision, dysarthria (possible stroke)
  • Severe ear pain, drainage, or fever (otitis or mastoiditis)
  • Bleeding from a bite site lasting more than 24 to 48 hours
  • Spreading redness or pus near the ear (cellulitis)
  • Fever above 38.0 C / 100.4 F or chills
  • Hives, throat tightness, or breathing difficulty
  • Bleeding from a bite site that soaks through more than one dressing per hour
  • Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
  • New persistent vertigo lasting more than 24 hours that does not feel like a usual Meniere attack

What this does NOT mean

  • This is not FDA-cleared for Ménière's disease.
  • Historical accounts and clinician anecdote do NOT establish efficacy beyond placebo for an episodic, fluctuating condition.
  • Mechanism rationale does NOT establish clinical efficacy.
  • Leech therapy will NOT cure Ménière's disease or prevent attacks.
  • Leech therapy is not a substitute for ENT/otology evaluation and evidence-based therapy.

Clinical Profile

Category
ENT
ICD-10
H81.01, H81.02, H81.03
Safety tier
Medium

Evidence Summary

No clinical study of leech therapy for Ménière's disease was identified in PubMed, Europe PMC, Crossref, ClinicalTrials.gov or the Baskova and Isakhanyan 2004 monograph, which lists Ménière's disease only among indications recommended in a 1983 German textbook (Bottenberg), not as a studied condition. Leeches were used for vertigo as a bloodletting practice before Ménière's disease was recognized as an inner-ear disorder (Baloh 2000, Neurology). Any use is investigational. A proposed mechanism involving reduction of endolymphatic pressure through systemic effects on fluid dynamics is speculative and no source for it was found. Standard management (low-sodium diet, betahistine, diuretics, intratympanic dexamethasone or gentamicin, vestibular rehabilitation, endolymphatic sac surgery) remains primary. Leech therapy is only an exploratory adjunct under ENT supervision.

What the books describe

Below is a summary of what books on hirudotherapy say about this condition. These are the authors’ observations, not a proven effect and not a promise of results. Hirudotherapy has contraindications; the decision is made by a physician.

  • Baskova and Isakhanyan name Meniere’s disease only in a list: in the chapter on neurological practice they write that, according to the conclusion of Bottenberg (1983), the method is indicated in a number of lesions of the nervous system, and Meniere’s disease is named among them[B1].
  • Baskova and Isakhanyan give no observations, results or description of treatment specifically for Meniere’s disease[B1].
  • Whether the authors themselves share this conclusion of Bottenberg is not clear from the text: in their own lists of indications (chapter 17), for neurology and for otorhinolaryngology, Meniere’s disease does not appear[B1].
  • Michalsen et al. do not mention Meniere’s disease and do not write about vertigo as an indication for hirudotherapy[B3].
  • Baskova and Isakhanyan give the general contraindications to hirudotherapy in chapter 17, among them hemophilia, hemorrhagic diatheses, anemias and concurrent prescription of anticoagulants (their list is longer); Flecken and Michalsen, in the chapter on contraindications, name congenital or acquired hemophilia and taking anticoagulants as an absolute contraindication[B1][B3].

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)

Contraindications

  • Hemophilia or another bleeding disorder
  • Taking anticoagulants (blood thinners such as warfarin or heparin)
  • Anemia or suppressed blood formation
  • Low blood pressure, shock, collapse or fainting
  • Severe wasting (cachexia)
  • Intolerance of leeches or a history of severe allergic reactions
  • Pregnancy
  • Stomach or duodenal ulcer, erosive gastritis
  • Acute infectious disease or high fever
  • Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
  • Drinking alcohol at the time of treatment
  • No consent from the patient
  • Acute vertiginous crisis (treat acutely first)
  • Recent (<3 months) ear surgery
  • Recent intratympanic gentamicin (<6 weeks)

Related Conditions

References

  • [B1]

    Баскова И.П., Исаханян Г.С. Гирудотерапия. Наука и практика [Hirudotherapy: Science and Practice]

    Москва: Монолит(2004)https://search.rsl.ru/ru/record/01007959553

    Monograph in Russian, 506 pp., ISBN 5-89527-058-1. Chapter 15: sensation at the bite, length of the session; secretion kininases and pain.

  • [B3]

    Michalsen A., Roth M., Dobos G. Medicinal Leech Therapy

    Stuttgart — New York: Thieme(2007)https://books.google.com/books?vid=ISBN9781588905635

    ISBN 978-3-13-143581-1 / 978-1-58890-563-5. Chapter 9, p. 107: perceptions of the bite — a local dragging pain lasting around one to five minutes.

The information on this page is based on the hirudotherapy books listed under References and reflects the experience their authors describe. Sensations and results differ from person to person. This information is not medical advice, a diagnosis or a prescription, and it does not replace an examination by a physician. Do not stop or change any prescribed treatment without your physician. Hirudotherapy has contraindications.

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.